Abstract
Introduction
The MEN1 gene is located on chromosome 11q13, which is mutated in patients with an inherited tumour syndrome, multiple endocrine neoplasia type 1 (MEN1) [1] . MEN1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours, mimicking human MEN1 syndrome, indicating that MEN1 as a bona fide tumour suppressor gene in endocrine tumours [2] . Recently, several [3, 4] , and it is required for maintenance of Hox family gene expression, and initiation of MLL-mediated leukemogenesis and myeloid transformation [3, 5, 6] . Recently, we have found that menin represses PTN transcription through Polycomb gene-mediated trimethylation of H3K27 and development of lung adenocarcinoma [7] .
reports have demonstrated that MEN1 is associated with non-endocrine tumours. For instance, menin has been shown to associate with trxG family proteins in a histone methyltransferase complex including trxG proteins MLL (mixed lineage leukaemia), retinoblastoma binding protein 5, WD repeat domain 5 and ASH2 (absent, small or homeotic) and promote histone 3 Lysine 4 (H3K4) methylation at the promoter of target genes
Malignant melanoma is the deadliest form of skin cancer, which is an increasing worldwide health problem because of its highly aggressive and drug-resistant nature [8] . Recent advances in understanding development and maintenance of melanoma provide novel insights into the molecular mechanisms. Kit/stem-cell factor (SCF) signalling and Mitf-dependent transcription is essential for melanoma initiation and development [8] . Disruption of Mitf in melanocytes or melanoma triggered apoptosis that can be blocked by B cell lymphoma 2 (Bcl-2) overexpression [9] . Genome-wide RNA-interference screening has uncovered 17 genes, including insulin like growth factor binding protein (IGFBP7), which have a central role in activated BRAF oncogene (BRAFV600E)-mediated apoptosis of melanocyte [10] . Selective [11] . These findings indicate a key role of Mitf, BRAF and BCL2 in promoting progression of melanoma, and partly explained the wellknown treatment resistance of melanoma. Pleiotrophin (PTN) is a heparin-binding growth factor that is highly expressed in certain solid cancers, including melanoma [12, 13] . Targeted disruption of PTN decreases melanoma tumour growth, metastasis and angiogenesis [14, 15] . PTN-dependent cell growth required both mitogen-activated protein kinase (MAPK) and pI3-kinase activity [16] . In melanoma, both MAPK and phosphatidylinositol 3-kinase (pI3K)-serine/threonine protein kinase (AKT) signalling pathways are constitutively activated through multiple mechanisms, and they exert a crucial regulating role in malignant phenotype of melanoma [17] . These 
inhibition of B-Raf drives oncogenic RAS-dependent BRAF binding to C-Raf, CRAF activation and mitogen-activated protein kinase kinase (MEK)-extracellular signal regulated kinase (ERK) signalling, revealing another paradigm of BRAF-mediated signalling that promotes tumour progression

Materials and methods
Cell Culture and gene transfection
RT-PCR and real-time qRT-PCR
Regular RT-PCR and quantitative RT-PCR (qRT-PCR)
were performed as previously described [7] , using an ABI PRISM 7300 detection system (ABI, Foster, CA, USA) with primers listed in Table S1 . The RT-PCR reactions were repeated at least for three times.
Western blotting
The Western blot detections were performed as described [7] . Antibodies are listed in Table S2 . 
Methylation-specific PCR (MSP)
Genomic
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed as previously described [7] . Briefly [7] . 
Data analysis and statistics
Results
Menin inhibits proliferation and migration of melanoma cells
Loss or mutation of MEN1 acutely promotes pancreatic islet cell proliferation [21, 22] . We have also found that menin suppresses proliferation of lung cancer cells, but the MEN1 point mutations, A242V and L22R, which were identified from inherited MEN1 patients [23] , lost or partially lost ability to repress cell proliferation [7] . [14] . Menin has been shown to control endocrine cell migration and cell-cell adhesion through interacting with a scaffold protein, IQ motif containing guanosine triphosphatase (GTPase) activating protein 1 [24] . We also found that menin expression was markedly reduced in 23% of certain lung adenocarcinoma, which was correlated with lymph node metastasis [7] .
Therefore, we performed a modified transwell chamber assay to evaluate the impact of stably ectopic menin expression on migration of melanoma cells. The results indicated that MEN1 overexpression significantly decreased migration of B16 cells (Fig. 1E, P Ͻ 0.05) and A375 cells (Fig. S1c and d). We next used an alternative approach, the scratch wound assay, to compare the motility of mock and menin overexpressing B16 cells. The extent of wound closure achieved by control cells within 48 hrs of wounding was much higher than that menin overexpressed B16 cells (Fig. 1F and G). The dramatic difference in wound healing between these two types of cells reinforces the notion that menin represses migration of melanoma cells. These results reveal a previously unappreciated function for menin in suppressing proliferation and migration of melanoma cells.
Menin inhibits melanoma cells partly through repressing PTN signalling
To elucidate how menin represses proliferation and migration of melanoma cells, we turned our attention to the impact of menin on expression of certain signalling pathways. Our previous work has
shown that menin suppresses lung cancer cell proliferation and migration partly through epigenetically repressing transcription of growth factor PTN [7] . PTN is a heparin-binding growth factor involved in the differentiation and proliferation of neuronal tissue during embryogenesis, and is highly expressed in certain solid tumours including melanoma and breast carcinoma cells [12, 13] . PTN binds to cell surface receptor RPTP ␤/ and exerts multiple functions including cell proliferation, adhesion and migration [25] [26] [27] 
Menin represses tumour growth and metastasis of melanoma cells in vivo
Fig. 1 Menin inhibits proliferation and migration of melanoma cells. (A) The efficiency of menin overexpression was detected by Western blot in B16 cells. (B) The proliferation of B16 cells which was stably transfected with either pMX-puro or pMX-menin was estimated by MTT assay. (C) The efficiency of menin overexpression was detected by Western blot in A375 cells. (D) The proliferation of A375 cells, which were stably transfected with either vector or menin, was detected by BrdU assay. (E) Stably transfected B16 cells were added to the upper filter, and cell migration was determined. (F and G) Quantification of the time-dependent effects of menin overexpression on cell motility (wound width
Fig. 2 Menin represses proliferation and migration of melanoma cells partly through PTN signalling. (A) Men1, PTN, RPTP ␤/, VEGF, VEGFc and bFGF mRNA levels were detected by RT-PCR. (B) The efficiency of menin overexpression and the effect of Men1 expression on PTN, RPTP ␤/ and VEGF expression were determined by Western blotting and ␤-actin was used as loading control. (C) B16 cells were transfected with either vector expressing shRNAs against Luc or one of the two shRNAs against PTN and selected by G418. The efficiency of PTN silencing was determined by RT-PCR. (D) The proliferation of the selected B16 cells was estimated by MTT assay. (E) The selected B16 cells were added to upper filter and cell migration was determined. (F and G) B16 cells were transfected with either vector expressing shRNAs against Luc or one of the there shRNAs against RPTP ␤/ and selected by G418. The efficiency of RPTP ␤/ silencing was determined by RT-PCR and Western blotting. (H) The selected B16 cells were added to upper filter and cell migration was determined.
various periods of time prior to analysis. The results indicated that pERK1/2 was rapidly increased after exposure to rhPTN at 15-60 min. (Fig. 4B). It showed that menin regulated activation of ERK1/2 partly through repressing PTN. These results suggest that FAK signalling may link menin/PTN to cell proliferation and migration partly through regulating pI3K and ERK1/2 pathways. To further confirm this observation, we determined whether pI3K and ERK1/2 signalling were necessary for the menin/PTN regulating phenotypes of melanoma cells. To this end, A375 cells were treated with either LY294002 or U0126, which are specific inhibitors for pI3K
and MEK1/2, respectively. As expected, both LY294002 and U0126 decreased proliferation of A375 cells in a dose-dependent manner (Fig. 4C and D) . Migration of A375 cells treated with either LY294002 or U0126 was also reduced (Fig. 4E and F) . ␤-catenin acts as a key factor in E-cadherin-mediated cell-cell adhesion [30] . Rho, Rac1 and Cdc42 [31] . Hence, we further examined if menin controls cell migration partly through Rho family signalling. (Fig. S2b) . (Fig. S3a) . Meanwhile, the dose-response result also indicates that menin was increased after exposure to indicated concentrations of cisplatin at 16 hrs (Fig. S3b) . However, there was no significant correlation between menin levels and sensitivity of melanoma cell lines to dacarbazine (Fig. S3c and (Fig. S3e) . Further studies indicated that menin repressed phosphorylation (S139) of ␥-H2AX, a marker of DNA damage repair, and cell cycle regulators, such as cyclin B1 and B2 (Fig. S3f) 
We further determined if menin/PTN regulated cell migration was dependent on ␤-catenin signalling. However, menin did not effectively suppress expression and phosphorylation (Tyr 142) of ␤-catenin (Fig. S2b). Cell morphology and migration were regulated by members of the Rho family of small GTPases, including © 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 3 Menin represses tumour growth and metastasis of melanoma cells in vivo. (A) The efficiency of menin overexpression was determined by Western blotting. (B) Menin overexpressing B16 cells were injected subcutaneously into nude mice and tumour formation was examined day 14 after transplantation. N ϭ 8, *P Ͻ 0.05. (C) The efficiency of PTN silencing was determined by Western blotting. (D) The PTN-shRNA expression B16 cells were injected subcutaneously into nude mice, and tumour formation was examined day 14 after transplantation
Ectopic menin expression did not alter the amount of either activated forms (GTP bound) or the total amount of Rho, Rac1 and Cdc42 in A375 cells
Next, we determined whether the level of expression of menin in melanoma cell lines is correlated with cell sensitivity to the cytotoxic effects of cisplatin and dacarbazine, the two most commonly used drugs for treating malignant melanoma. The time-course results indicate that menin was gradually increased after exposure to cisplatin at 0-24 hrs
d). Because it is well known that menin can induce cell apoptosis [32], we determined whether menin could serve as a means to enhance killing of malignant melanoma cells. Overexpression of menin indeed increased cisplatin induced apoptosis of A375 cells
DNA Methylation of the MEN1 promoter correlates with menin inactivation in A375 cells
Since we observed a crucial role for menin in repressing phenotype of melanoma cells, we wondered if the menin protein level is altered in patients' primary melanoma. We examined 12 malignant melanoma samples and 6 pigmented nevus. These tumours were from male and female patients with ages ranging from 28 to 88 (Table S3) [7] . Menin was easily detected in the nucleus of the normal six pigmented nevus cells (Fig. 5A) . However in melanoma tumours, staining for menin was slightly weaker (three cases) or undetectable (nine cases), as compared to that in the pigmented nevus cells (Fig. 5B, C and Table S3 ). To determine the cause for inactivation of menin in A375 cells, we designed the primers to determine if MEN1 was mutated (Fig. S4) . Unexpectedly, DNA sequencing data did not reveal any mutation in the sequence of MEN1.
. Sections from paraffin-embedded samples were stained with affinity-purified anti-menin antibody for immunohistochemistry (IHC) staining, and the specificity of the anti-menin antibody was verified in menin-null and menin-expressing cells
Transcriptional silencing of tumour suppressor genes, associated with DNA hypermethylation of CpG islands [33] . Hence we considered if reduced menin expression is related to epigenetic regulation. In MSP analysis, we designed methylation-specific primers and unmethylation-specific primers which were targeted to CpG sites (Fig. 6A) , and examined the methylation status of the MEN1 promoter in A375 cells using real-time qPCR. In order to clarify the functional association between MEN1 promoter methylation, 5Ј-aza-dc, an agent reducing DNA methylation, was used to treat A375 cells. The quantitative methylation-specific PCR (qMSP) results showed that the level of DNA hypermethylation at the MEN1 promoter was reduced by treatment with 5Ј-aza-dc in A375 cells (Fig. 6B) . After 7 days treatment with 5Ј-aza-dc at 3 M or 5 M, the increased MEN1 mRNA re-expression was detected by real-time qRT-PCR (Fig. 6C) .
Furthermore, we also determined if DNA methytransferase 1 (DNMT1) binds to the MEN1 promoter using ChIP assay. We designed two primers used for ChIP assays at Men1 promoter loci (Fig. 6D) . In A375 cells, an interaction between DNMT1 and the promoter of MEN1 could be detected (Fig. 6E, lane 3) . Following exposure to 5Ј-aza-dc, the interaction between the DNMT1 and the promoter of MEN1 was reduced (Fig. 6E, lane 6) . To explore whether treatment with 5Ј-aza-dc affects proliferation and migration (Fig. 6F) .
In addition, MTT assay confirmed that treatment with 5Ј-aza-dc reduced the number of A375 cells (Fig. 6G) . A similar result was obtained using the BrdU incorporation assay (Fig. 6H) [2] . Menin interacted with MLL and promoted the development of leukaemia through binding to the locus of Hox family genes and highlight the level of H3K4me3 [3] [4] [5] [6] . Recently, we have found that menin inhibits lung cancer cell proliferation and migration via epigenetic repression of PTN signalling [7] . Various skin tumours of mesenchymal origin, including angiofibromas, collagenomas and lipomas, as well as malignant melanoma, were detected in MEN1 syndrome patients [18, 19] S3 (a, c) 
